Apotea

Research Apotea (APOTEA) on Bullrun: valuation model: 7.1% overvalued, market cap SEK 7.72B, P/E 32.7, dividend yield 0.8%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerAPOTEA
• ExchangeST
• CountrySweden
• SectorHealthcare
• IndustryPharmaceutical Retailers
• CurrencySEK
• Valuation signal7.1% overvalued
• Market capSEK 7.72B
• P/E32.7
• Dividend yield0.8%
• Financial periodFY2024
• RevenueSEK 6.54B
• Revenue growth20.0%
• Net incomeSEK 212.00M
• Free cash flowSEK 43.40M
• Gross margin27.3%

Valuation Snapshot

Bullrun's latest valuation model marks Apotea as 7.1% overvalued; latest market cap is SEK 7.72B; P/E is 32.7; dividend yield is 0.8%.

About Apotea

Apotea AB (publ) operates an online pharmacy in Sweden. The company offers products in the areas of allergy, face, baby, child and parent, bite and sting, preparedness, animal, fever and aches, cold, home and household, aid, hair removal and shaving, hair care, hands and feet, intimate, and dietary supplements.

Frequently asked questions

Is Apotea overvalued or undervalued?

Bullrun's valuation model currently marks Apotea as 7.1% overvalued.

What is Apotea's market cap?

Apotea's market capitalization is SEK 7.72B.

What is Apotea's P/E ratio?

Apotea's price-to-earnings (P/E) ratio is 32.7.

Does Apotea pay a dividend?

Apotea has a dividend yield of 0.8%.

What does Apotea do?

Apotea AB (publ) operates an online pharmacy in Sweden. The company offers products in the areas of allergy, face, baby, child and parent, bite and sting, preparedness, animal, fever and aches, cold, home and household, aid, hair removal and shaving, hair care, hands and feet, intimate, and dietary...